Last reviewed · How we verify
RLD2101
RLD2101 is a small molecule that targets the SGLT2 receptor.
RLD2101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | RLD2101 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
RLD2101 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (PHASE3)
- Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RLD2101 CI brief — competitive landscape report
- RLD2101 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI